<DOC>
	<DOCNO>NCT01027065</DOCNO>
	<brief_summary>This study design evaluate safety biological active dose new experimental drug , IL-7 , combination anti viral therapy vaccine patient Hepatitis B chronic infection .</brief_summary>
	<brief_title>Dose Escalation Interleukin-1 ( IL-7 ) Added Antiviral Treatment Vaccination HBeAg-negative Chronic Hepatitis B Virus ( HBV ) Infected Patients</brief_title>
	<detailed_description>This Phase I/IIa inter-patient dose-escalation study assess weekly dos Interleukin-7 ( CYT107 ) HBeAg-negative chronic hepatitis B infect adult patient . The dose escalation aim establish safety biologically active dos CYT107 add current antiviral therapy entecavir tenofovir vaccination . At dose level , study patient receive one subcutaneous administration CYT107 per week total 4 . Groups 8 patient enter dose level CYT107 . Three dose level plan . At dose level , patient randomize 2 arm treatment : tritherapy ( CYT107 , vaccine antiviral treatment ) bitherapy ( CYT107 vaccine ) . Each treatment group compose 4 patient , 3 receive experimental treatment , 1 current antiviral treatment ( control patient ) . According treatment arm , eligible patient initially receive vaccine treatment group tritherapy , thereafter , CYT107 add cycle four weekly injection ( control patient ) define dose level . If treatment group tritherapy , patient receive 2 additional dos vaccine . The treatment phase tritherapy group first vaccine D0 last vaccine W12 include CYT107 administration W4 W7 . The treatment phase bitehrapy group W4 W7 correspond CYT104 injection . The patient follow regular basis reach 52 week D0 . Participants 1 overnight hospitalization 12 clinic visit period 55 week . During visit follow may do : - medical history , physical examination , blood test - electrocardiogram ( ECG ) - chest X-Ray - liver/spleen image - urine test</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Chronic HBVinfected patient HBeAgnegative patient Age &gt; 18 year Patients active chronic hepatitis start antiviral treatment Patient HBV DNA undetectable ( &lt; 70 copies/ml ) stable least 3 month entecavir tenofovir treatment . Ongoing treatment entecavir tenofovir screen Note : previous treatment pegylated IFN monotherapy , start entecavir tenofovir , acceptable Infection HCV Infection HIV1 /or HIV2 Apart HBV infection , presence active infection require specific treatment hospitalization Previous treatment lamivudine and/or nucleoside analogues Inactive carrier Cirrhosis Other liver disease ( notably alcoholic , metabolic immunological origin ) History clinical autoimmune disease active autoimmune disease Type I diabetes mellitus Severe asthma , presently chronic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>interleukin-7</keyword>
	<keyword>immune-based therapy</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>HBe negative</keyword>
	<keyword>HBV vaccination</keyword>
	<keyword>entecavir</keyword>
	<keyword>tenofovir</keyword>
	<keyword>chronic hepatitis</keyword>
	<keyword>immune specific response HBV</keyword>
	<keyword>phase 1/2a</keyword>
	<keyword>viral disease</keyword>
	<keyword>liver disease</keyword>
</DOC>